Epsilon Molecular Engineering (EME) Inc. is an evolutionary molecular engineering based biopharmaceutical drug discovery company. EME was established in 2016 as a venture company from Saitama University in Japan, and has proprietary technologies, unique cDNA display libraries of the heavy chain single domain antibodies (VHH) and cyclic peptides with large diversity (10^13-14), and high-throughput screening methods using next-generation sequence, FACS and Machine learning (Bioinformatics). EME is, currently, conducting several joint research projects, including COVID-19, and 17 ongoing inhouse projects in the arias of cancer, inflammation, and Alzheimer’s disease, etc.